Adagio Medical Treats First Patient With Its vCLAS Ultra Ultra-Low Temperature Ablation System Under FDA's Expanded Access Authorization
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful
Adagio Medical got permission to treat a real patient with a new heart-rhythm machine that uses super-cold technology. This is an early step that shows the device might work, but the company is still testing it and hasn't proven it's better than other options yet.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.